Genmab A/S (NASDAQ:GMAB) Sees Unusually-High Trading Volume – Should You Buy?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) shares saw strong trading volume on Thursday . 1,599,957 shares changed hands during mid-day trading, a decline of 16% from the previous session’s volume of 1,915,176 shares.The stock last traded at $33.3840 and had previously closed at $34.11.

Analysts Set New Price Targets

Several brokerages recently commented on GMAB. Truist Financial assumed coverage on shares of Genmab A/S in a report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price for the company. BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. New Street Research set a $43.00 price objective on shares of Genmab A/S in a research note on Wednesday, July 22nd. The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. Finally, Guggenheim lifted their target price on Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Genmab A/S Trading Down 2.1%

The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The firm has a fifty day moving average price of $28.49 and a 200 day moving average price of $27.92. The company has a market cap of $20.83 billion, a price-to-earnings ratio of 26.31, a P/E/G ratio of 1.96 and a beta of 0.83.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.17. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. As a group, equities analysts predict that Genmab A/S Sponsored ADR will post 1.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently bought and sold shares of the company. Legacy Wealth Asset Management LLC boosted its position in Genmab A/S by 164.1% during the second quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock worth $2,806,000 after purchasing an additional 63,484 shares during the period. GAMMA Investing LLC lifted its stake in shares of Genmab A/S by 16.4% during the 2nd quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock worth $109,000 after buying an additional 561 shares during the last quarter. Summitry LLC boosted its holdings in shares of Genmab A/S by 5.3% during the 1st quarter. Summitry LLC now owns 11,170 shares of the company’s stock worth $300,000 after buying an additional 567 shares during the period. BankChampaign National Association bought a new stake in shares of Genmab A/S during the 1st quarter worth about $687,000. Finally, Strategic Investment Advisors MI acquired a new position in Genmab A/S in the 1st quarter valued at about $137,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.